Company Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally.
The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.
It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations.
In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers.
It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011.
Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2008 |
| IPO Date | Apr 30, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 655 |
| CEO | Ms. Kathryn Haviland |
Contact Details
Address: 45 Sidney Street Cambridge, Massachusetts 02139 United States | |
| Phone | 617-374-7580 |
| Website | blueprintmedicines.com |
Stock Details
| Ticker Symbol | BPMC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001597264 |
| CUSIP Number | 09627Y109 |
| ISIN Number | US09627Y1091 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Kathryn Haviland | President, Chief Executive Officer and Director |
| Alexis A. Borisy A.M. | Co-Founder and Director |
| Michael Landsittel | Chief Financial Officer |
| Christina Rossi | Chief Operating Officer |
| Tracey L. McCain Esq. | Executive Vice President, Chief Legal and Compliance Officer and Secretary |
| Dr. Fouad Namouni M.D. | President of Research and Development |
| Ariel Hurley | Senior Vice President, Finance and Principal Accounting Officer |
| Dr. Christopher K. Murray Ph.D. | Senior Vice President of Technical Operations and Chief Technical Operations and Quality Officer |
| Dr. Percy H. Carter M.B.A., Ph.D. | Chief Scientific Officer |
| Jenna Cohen | Senior Director and Head of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 10, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Mar 28, 2024 | 144 | Filing |
| Mar 15, 2024 | 144 | Filing |
| Mar 15, 2024 | 144 | Filing |
| Mar 13, 2024 | 144 | Filing |
| Mar 4, 2024 | 144 | Filing |
| Feb 28, 2024 | 144 | Filing |
| Feb 22, 2024 | 8-K | Current Report |
| Feb 16, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 15, 2024 | 10-K | Annual Report |